scholarly journals Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum-based chemotherapy

Cancer ◽  
2002 ◽  
Vol 95 (11) ◽  
pp. 2408-2413 ◽  
Author(s):  
Manolo González-Barón ◽  
Amdio Ordóñez ◽  
Rosa Franquesa ◽  
Manuel Constenla ◽  
Joaquin Montalar ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Recombinant Human Erythropoietin ◽  
Human Erythropoietin ◽  
Predicting Factors ◽  
Platinum Based Chemotherapy

Recombinant human erythropoietin for anaemia in Chinese cancer patients on chemotherapy

1995 ◽  
Vol 7 (4) ◽  
pp. 272 ◽  
Author(s):  
A.T.C. Chan ◽  
W.T. Leung ◽  
J. Lin ◽  
W. Yeo ◽  
P.J. Johnson
Keyword(s):  
Cancer Patients ◽  
Recombinant Human Erythropoietin ◽  
Human Erythropoietin ◽  
Chinese Cancer Patients

Intravenous Iron Optimizes the Response to Recombinant Human Erythropoietin in Cancer Patients With Chemotherapy-Related Anemia: A Multicenter, Open-Label, Randomized Trial

2004 ◽  
Vol 22 (7) ◽  
pp. 1301-1307 ◽  
Author(s):  
Michael Auerbach ◽  
Harold Ballard ◽  
J. Richard Trout ◽  
Marilyn McIlwain ◽  
Alan Ackerman ◽  
...  
Keyword(s):  
Randomized Trial ◽  
Cancer Patients ◽  
Recombinant Human Erythropoietin ◽  
Transferrin Saturation ◽  
Oral Iron ◽  
Iron Dextran ◽  
Iron Group ◽  
Open Label ◽  
Human Erythropoietin ◽  
Iv Iron

PurposeRecombinant human erythropoietin (rHuEPO) is the standard of care for patients with chemotherapy-related anemia. Intravenous (IV) iron improves hemoglobin (Hb) response and decreases dosage requirements in patients with anemia of kidney disease, but its effect has not been studied in randomized trials in cancer patients.MethodsThis prospective, multicenter, open-label, randomized trial enrolled 157 patients with chemotherapy-related anemia (Hb ≤ 105 g/L, serum ferritin ≤ 450 pmol/L or ≤ 675 pmol/L with transferrin saturation ≤ 19%) receiving subcutaneously rHuEPO 40,000 U once weekly to: (1) no-iron; (2) oral iron 325 mg twice daily; (3) iron dextran repeated 100mg IV bolus; or (4) iron dextran total dose infusion (TDI). Hb and quality of life (QOL) were measured at baseline and throughout.ResultsAll groups showed Hb (P < .0001) increases from baseline. Mean Hb increases for both IV iron groups were greater (P < .02) than for no-iron and oral iron groups. The percentage of patients with hematopoietic responses was higher (P < .01) in both IV iron groups (each case 68%) compared with no-iron (25%) and oral iron (36%) groups. IV iron groups showed increases in energy, activity, and overall QOL from baseline, compared with a decrease in energy and activity for no-iron group and no change in activity or overall QOL for oral iron group.ConclusionrHuEPO increases Hb levels and improves QOL in patients with chemotherapy-related anemia. Magnitude of Hb increase and QOL improvement is significantly greater if IV iron is added.

Sign in / Sign up

Export Citation Format

Share Document